Back

Teva announces appointment of New President & CEO, Teva Generics Europe

Richard Daniell to assume position of President & CEO, Teva Generics Europe, and succeeds Dipankar Bhattacharjee

Amsterdam, December 13, 2016 – Teva Europe BV has announced the appointment of Richard Daniell to the position of President & CEO of Teva Generics Europe, succeeding Dipankar Bhattacharjee who has been promoted to be President and CEO, Global Generic Medicines. Mr. Daniell served as General Manager of Teva UK Limited from 2011 to 2015, and over the last year has been Teva’s Chief Integration Officer overseeing the integration of Actavis into Teva. 

As General Manager of Teva UK Limited, Mr. Daniell consolidated Teva’s position as the leading generics supplier in the UK; and most recently he led the integration program to bring together Actavis and Teva following the announcement of the transaction in 2015 and the close in August this year. “Richard has over twenty five years’ experience in the generics industry, and has held several key senior commercial roles in the generics industry, both before and since joining Teva through the 2006 acquisition of IVAX,” explained Dipankar Bhattacharjee, President and CEO for Teva Global Generic Medicines Group. “He has shown visionary leadership, has built high-performing teams across the company and has an impressive record in driving commercial success,” Mr. Bhattacharjee added.

Richard Daniell commented on his appointment: “I’m deeply honored to have been appointed to lead Teva’s European business. Teva has the skills, capabilities and products to be the best in generics and I’m proud to be asked to lead our strong and talented European team.”

Richard Daniell – Key Biographical Details

Richard Daniell has worked for Teva and its predecessors for over twenty five years, joining IVAX in 1990. Born in New Zealand, Richard has a degree in chemistry and has lived in the UK for most of his adult life. Richard was appointed as General Manager for Teva in the UK in 2012. In 2015, he became Chief Operating Officer, Growth Markets region before leading the Actavis Integration Management Office. In his new role, Richard will be based in Amsterdam, the Netherlands. 

About Teva

With its European headquarters in Amsterdam, the Netherlands, Teva is Europe’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area to help patients in nearly forty countries across the region. In specialtymedicines Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva uses its generics and specialtycapabilities to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in Europe in 2015 were €4.9 billion. For more information, visit www.tevapharm.com.

PR Contacts:

Iris Beck Codner 
Denise Bradley
Paul Williams

Israel
United States
Europe

972 (3) 926-7687
(215) 591-8974
+31 (0)20 2193 312